A multicenter, randomized, controlled trial of S-1/Cisplatin vs.Docetaxel/Cisplatin for treatment of

来源 :第十七届全国临床肿瘤学大会暨2014年CSCO学术年会 | 被引量 : 0次 | 上传用户：missAma

【摘要】

：

【作者】

：

Jianhua Chang Yuankai Shi Jianxing He Mengzhao Wang Baohui Han Xiaoqing Liu Gongyan Chen Caicun Zhou Jiwei Liu Hongming Pan Cheng Huang Shucai Zhang Jifeng Feng Xiaoyan Lin Jie Wang Jianjin Huang Fang

【机构】

：

Fudan University Shanghai Cancer Center, Shanghai, CHINA

【出处】

：

第十七届全国临床肿瘤学大会暨2014年CSCO学术年会

【发表日期】

：

2014年11期

下载到本地 , 更方便阅读

下载此文赞助VIP

声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架

论文部分内容阅读

Objective: Platinum based doublet chemotherapy is standard treatment for treatment na(i)ve advanced NSCLC pts, although molecularly targeted therapy can improve outcome of selected patients who harbors driver gene mutation.S-1, a oral fluoropyrimidine, has been investigated to treat NSCLC.S-1 was active enough to show non-inferiority in two randomized phase Ⅲ trials either in combination with Carboplatin and Cisplatin (CDDP) compared with the standard platinum doublet chemotherapy in Japanese pts with NSCLC.

其他文献

Safety and clinical activity of pembrolizumab (pembro, MK-3475) as initial therapy in patients with

Objective:Programmed death-1 (PD-1) receptor-ligand interaction inhibits T cell activation against tumor cells.Pembro is a potent and highly selective humanized monoclonal antibody against PD-1 design

会议

Functional Polymorphisms in Cancer Stem Cell Marker Gene CD133 Predict Local Recurrence and Distant

Objective: Cancer stem cells (CSCs) are believed to cause local recurrence, distant metastasis, radiotherapy and chemotherapy resistance.We hypothesized that genetic variation in CD133 (the official n

会议

Utilizing Pemetrexed plus Platinum as First-line Treatment in East-Asian Elderly Patients with Advan

Objective: A meta-analysis was recently conducted in East-Asian advanced non-squamous non-small cell lung cancer (nsq-NSCLC) patients based on available individual patient data from three randomized p

会议

Drug Exposure and Safety of Pemetrexed/platinum versus Other Platinum-based Doublets as First-line T

Objective: Pemetrexed in combination with platinum has shown better efficacy and less toxicity than other standard first-line chemotherapies for patients with advanced non-squamous non-small cell lung

会议

Visceral pleural invasion is associated with post-operative poor prognosis of 261 Chinese patients w

Objective: To determine the association between visceral pleural invasion (VPI) and post-operative prognosis in early stage non-small cell lung cancer (NSCLC).Method: Between November 2007 and Novembe

会议

Clinicopathological characteristics and outcome of 59 Chinese patients with adenosquamous lung carci

Objective: Adenosquamous lung carcinoma (ASC) is a rare type of lung cancer by being histologically mixed adenocarcinoma and squamous cell carcinoma and is very aggressive with a poor prognosis.This s

会议

Met-positive (Met+), locally advanced or metastatic non-small cell lung cancer (NSCLC) with epiderma

Objective: A secondary mutation in the EGFR (ie, T790M) and amplification of the c-Met proto-oncogene are the main causes of resistance to EGFR tyrosine kinase inhibitors (eg, gefitinib) in EGFRm+ NSC

会议

Single-nucleotide polymorphisms in VTI1A gene contribute to the susceptibility to non-small cell lun

Objective: This study was to evaluate the association between single-nucleotide polymorphisms (SNP) in VTI1A gene and the susceptibility to lung cancer in never-smoking Chinese patients, and investiga

会议

Overall survival (OS) with afatinib (A) vs gemcitabine/cisplatin (GC) in treatment-naive Chinese pat

Objective:A, an oral, irreversible ErbB family blocker, was compared with GC in 364 Asian pts with EGFR mut positive NSCLC, including 327 pts from China.PFS was significantly prolonged with A vs GC in

会议

Continuous Intravenous Pumping of Recombinant Human Endostatin (Endostar) Combined with Concurrent R

Objective: Preclinical models have shown that recombinant human endostatin (Endostar) can transiently normalize the tumor vasculature to make it more efficient for oxygen delivery, which provides a tr

会议

A multicenter, randomized, controlled trial of S-1/Cisplatin vs.Docetaxel/Cisplatin for treatment of

与本文相关的学术论文